BioHarvest Sciences (NASDAQ:BHST) Stock Price Up 1.4% – Time to Buy?

BioHarvest Sciences Inc. (NASDAQ:BHST)’s stock price traded up 1.4% during trading on Tuesday. The company traded as high as $1.52 and last traded at $1.47. Approximately 69,597 shares traded hands during mid-day trading, an increase of 113% from the average session volume of 32,657 shares. The stock had previously closed at $1.45.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on BHST. Weiss Ratings restated a “sell (d-)” rating on shares of BioHarvest Sciences in a research report on Monday, September 14th. Roth Capital reduced their price objective on BioHarvest Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, August 12th. Finally, Maxim Group reduced their price objective on BioHarvest Sciences from $12.00 to $5.00 and set a “buy” rating on the stock in a research note on Wednesday, August 12th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, BioHarvest Sciences has a consensus rating of “Hold” and an average target price of $6.50.

BioHarvest Sciences Price Performance

The firm has a market cap of $28.84 million, a P/E ratio of -2.83 and a beta of 0.94. The stock’s 50-day simple moving average is $1.93 and its two-hundred day simple moving average is $3.09.

BioHarvest Sciences (NASDAQ:BHST) last released its earnings results on Monday, August 10th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.04). The firm had revenue of $8.84 million during the quarter, compared to the consensus estimate of $9.45 million. BioHarvest Sciences had a negative return on equity of 58.30% and a negative net margin of 31.21%. As a group, sell-side analysts expect that BioHarvest Sciences Inc. will post -0.58 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of BHST. Silverberg Bernstein Capital Management LLC purchased a new position in BioHarvest Sciences during the 1st quarter valued at $113,000. True North Advisors LLC increased its stake in BioHarvest Sciences by 381.0% in the first quarter. True North Advisors LLC now owns 168,013 shares of the company’s stock worth $729,000 after purchasing an additional 133,085 shares during the period. Finally, Thompson Siegel & Walmsley LLC purchased a new stake in BioHarvest Sciences in the fourth quarter worth $1,945,000.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotechnology company developing and commercializing products made with its proprietary Botanical Synthesis technology. The company’s platform is designed to produce specific plant-based compounds, including polyphenols, without growing the entire plant. BioHarvest says the process may help generate consistent, standardized botanical ingredients for use in health and wellness products and pharmaceutical development.

The company’s principal commercial product is VINIA, a powdered whole-fruit botanical ingredient derived from red grape cells and marketed for its polyphenol content.